Search

Author/Creator Larkin, J

1. P095 Association between tissue oncostatin M expression and infliximab response in corticosteroid refractory acute severe ulcerative colitis. (25th January 2019)

Authors:
O'Connell, J; McDonagh, P; Clarke, N; Buckley, A; Dunne, C; Hartery, K; Larkin, J; MacCarthy, F; McCormack, P; McKiernan, S; Mehigan, B; Muldoon, C; Ryan, C; O'Sullivan, J; Kevans, D
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S133
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 1287PAdvanced melanoma treatment patterns in the modern era: United Kingdom (UK) real world retrospective chart review study. (23rd October 2018)

Authors:
Sacco, J J; Corrie, P G; Oladipo, O; Payne, M; Larkin, J; Talbot, T; Wagstaff, J; Cheetham, S; Stein, D; Soni, M; Coombs, C; Amadi, A; Wang, M; Ellis, J
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 76PCorrelative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma. (23rd October 2018)

Authors:
Lee, C-H; Motzer, R J; Glen, H; Michaelson, M D; Larkin, J; Minoshima, Y; Kanekiyo, M; Dairiki, R; Sachdev, P; Dutcus, C E; Funahashi, Y; Voss, M H
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. LBA44Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067). (23rd October 2018)

Authors:
Hodi, F S; Chiarion-Sileni, V; Gonzalez, R; Grob, J J; Rutkowski, P; Cowey, C L; Lao, C; Schadendorf, D; Wagstaff, J; Dummer, R; Ferrucci, P F; Smylie, M; Hill, A G; Hogg, D; Marquez-Rodas, I; Jiang, J; Rizzo, J; Larkin, J; Wolchok, J
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. 1251PAdverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. (23rd October 2018)

Authors:
Atkinson, V G; Hauschild, A; Santinami, M; Mandala, M; Chiarion Sileni, V; Larkin, J; Nyakas, M S; Dutriaux, C; Haydon, A; Mortier, L; Robert, C; Schachter, J; Schadendorf, D; Feng, X; de Jong, E; Mookerjee, B; Kefford, R; Dummer, R; Kirkwood, J M; Long, G V
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. 1250PEstimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. (23rd October 2018)

Authors:
Dummer, R; Schadendorf, D; Hauschild, A; Santinami, M; Atkinson, V G; Mandala, M; Chiarion Sileni, V; Larkin, J; Nyakas, M S; Dutriaux, C; Haydon, A; Mortier, L; Robert, C; Schachter, J; Feng, X; de Jong, E; Mookerjee, B; Kefford, R; Kirkwood, J M; Long, G V
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. 1278PHealth-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial. (23rd October 2018)

Authors:
Coens, C; Bottomley, A; Blank, C U; Mandala, M; Long, G V; Atkinson, V G; Dalle, S; Haydon, A; Lichinitser, M; Khattak, A; Carlino, M S; Sandhu, S K; Larkin, J; Puig Sarda, S; Ascierto, P A; Schadendorf, D; Ibrahim, N; Suciu, S; Robert, C; Eggermont, A M M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. 931TiPPRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. (23rd October 2018)

Authors:
Collinson, F; Brown, S; Buckley, H; Ainsworth, G; Howard, H; Poad, H; Carr, G; Banks, R E; Brown, J; Velikova, G; Larkin, J; Nathan, P; Powles, T B; Vasudev, N S
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗